These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10701364)

  • 1. A phase II study of 9-aminocamptothecin in patients with refractory breast cancer.
    Kraut EH; Balcerzak SP; Young D; O'Rourke MA; Petrus JJ; Kuebler JP; Mayernik DG
    Cancer Invest; 2000; 18(1):28-31. PubMed ID: 10701364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
    J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
    Pazdur R; Diaz-Canton E; Ballard WP; Bradof JE; Graham S; Arbuck SG; Abbruzzese JL; Winn R
    J Clin Oncol; 1997 Aug; 15(8):2905-9. PubMed ID: 9256134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
    Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM
    Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.
    Pazdur R; Medgyesy DC; Winn RJ; Dakhil SR; Moore DF; Scalzo A; Hoff PM; Arbuck SG; Abbruzzese JL
    Invest New Drugs; 1998-1999; 16(4):341-6. PubMed ID: 10426669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
    Kindler HL; Avadhani A; Wade-Oliver K; Karrison T; Mani S; Vokes EE
    Invest New Drugs; 2004 Aug; 22(3):323-7. PubMed ID: 15122080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
    Dahut W; Harold N; Takimoto C; Allegra C; Chen A; Hamilton JM; Arbuck S; Sorensen M; Grollman F; Nakashima H; Lieberman R; Liang M; Corse W; Grem J
    J Clin Oncol; 1996 Apr; 14(4):1236-44. PubMed ID: 8648379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
    Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
    J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
    Wilson WH; Little R; Pearson D; Jaffe ES; Steinberg SM; Cheson BD; Humphrey R; Kohler DR; Elwood P
    J Clin Oncol; 1998 Jul; 16(7):2345-51. PubMed ID: 9667249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
    Saltz LB; Kemeny NE; Tong W; Harrison J; Berkery R; Kelsen DP
    Cancer; 1997 Nov; 80(9):1727-32. PubMed ID: 9351540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
    Fumoleau P; Delgado FM; Delozier T; Monnier A; Gil Delgado MA; Kerbrat P; Garcia-Giralt E; Keiling R; Namer M; Closon MT
    J Clin Oncol; 1993 Jul; 11(7):1245-52. PubMed ID: 8315421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma.
    Argiris A; Heald P; Kuzel T; Foss FM; DiStasio S; Cooper DL; Arbuck S; Murren JR
    Invest New Drugs; 2001; 19(4):321-6. PubMed ID: 11561692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium.
    Hochberg F; Grossman SA; Mikkelsen T; Glantz M; Fisher JD; Piantadosi S
    Neuro Oncol; 2000 Jan; 2(1):29-33. PubMed ID: 11302251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
    Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
    Perez-Soler R; Fossella FV; Glisson BS; Lee JS; Murphy WK; Shin DM; Kemp BL; Lee JJ; Kane J; Robinson RA; Lippman SM; Kurie JM; Huber MH; Raber MN; Hong WK
    J Clin Oncol; 1996 Feb; 14(2):503-13. PubMed ID: 8636764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
    Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Levenback C; Chantarawiroj P; Gonzalez de Leon C; Kim EE; Madden T; Wallin B; Hord M; Verschraegen C; Raber M; Kavanagh JJ
    J Clin Oncol; 1996 May; 14(5):1552-7. PubMed ID: 8622071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.